Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.

Masayuki Kano,Koichi Hayano,Hideki Hayashi,Naoyuki Hanari,Hisashi Gunji,Takeshi Toyozumi,Kentaro Murakami,Masaya Uesato,Satoshi Ota,Hisahiro Matsubara

Annals of surgical oncology（2019）

引用 28|浏览30

暂无评分

摘要

The NAC DS group showed a high 3-year PFS compared with the surgery-first group, with standard S-1 postoperative chemotherapy or observation. NAC DS can be expected to be beneficial as the standard therapy for advanced gastric cancer and should be adopted for the test arm of a randomized controlled phase III trial.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要